SNPs most strongly associated with DLBCL survival, ordered by P value from the codominant model
| SNP . | Gene . | P* . | Deleterious genotype(s)† . | Patients with deleterious genotype, % . | HR‡ . | 95% CI . |
|---|---|---|---|---|---|---|
| rs2069807 | IL5d | <.001 | CT/TT | 2.9 | 4.56 | 1.98-10.5 |
| rs1126580 | IL8RB | .002 | AG/GG | 68.6 | 2.11 | 1.28-3.50 |
| rs1800587 | IL1A | .004 | CT/TT | 49.2 | 1.90 | 1.26-2.87 |
| rs17561 | IL1A | .03 | GT/TT | 46.6 | 1.56 | 1.04-2.35 |
| rs3176879 | VCAM1§ | .03 | AG/GG | 6.9 | 2.10 | 1.04-4.22 |
| rs1800795 | IL6 | .03 | GG/CG | 86.1 | 1.57 | 0.84-2.94 |
| rs1800797 | IL6 | .04 | GG | 40.6 | 1.47 | 0.99-2.21 |
| rs5491 | ICAM1§ | .04 | AT/TT | 2.3 | 2.80 | 1.01-7.72 |
| rs25645 | CSF3‖ | .04 | AA | 14.7 | 2.37 | 1.34-4.21 |
| rs1800896 | IL10 | .08 | AG/GG | 71.0 | 1.48 | 0.91-2.38 |
| rs1143634 | IL1B | .09 | CT/TT | 33.8 | 1.31 | 0.86-1.98 |
| rs1800629 | TNF | .09 | AG/AA | 33.1 | 1.44 | 0.95-2.18 |
| rs1801157 | CXCL12 | .09 | GG | 64.8 | 1.62 | 1.02-2.58 |
| rs1041163 | VCAM1 | .10 | TT | 69.4 | 1.35 | 0.88-2.08 |
| rs5361 | SELE‖ | .12 | AC/CC | 17.0 | 1.41 | 0.74-2.66 |
| rs2107356 | IL4R | .14 | CC/CT | 82.4 | 1.97 | 1.01-3.83 |
| rs1799724 | TNF | .15 | CC | 83.4 | 1.35 | 0.78-2.34 |
| SNP . | Gene . | P* . | Deleterious genotype(s)† . | Patients with deleterious genotype, % . | HR‡ . | 95% CI . |
|---|---|---|---|---|---|---|
| rs2069807 | IL5d | <.001 | CT/TT | 2.9 | 4.56 | 1.98-10.5 |
| rs1126580 | IL8RB | .002 | AG/GG | 68.6 | 2.11 | 1.28-3.50 |
| rs1800587 | IL1A | .004 | CT/TT | 49.2 | 1.90 | 1.26-2.87 |
| rs17561 | IL1A | .03 | GT/TT | 46.6 | 1.56 | 1.04-2.35 |
| rs3176879 | VCAM1§ | .03 | AG/GG | 6.9 | 2.10 | 1.04-4.22 |
| rs1800795 | IL6 | .03 | GG/CG | 86.1 | 1.57 | 0.84-2.94 |
| rs1800797 | IL6 | .04 | GG | 40.6 | 1.47 | 0.99-2.21 |
| rs5491 | ICAM1§ | .04 | AT/TT | 2.3 | 2.80 | 1.01-7.72 |
| rs25645 | CSF3‖ | .04 | AA | 14.7 | 2.37 | 1.34-4.21 |
| rs1800896 | IL10 | .08 | AG/GG | 71.0 | 1.48 | 0.91-2.38 |
| rs1143634 | IL1B | .09 | CT/TT | 33.8 | 1.31 | 0.86-1.98 |
| rs1800629 | TNF | .09 | AG/AA | 33.1 | 1.44 | 0.95-2.18 |
| rs1801157 | CXCL12 | .09 | GG | 64.8 | 1.62 | 1.02-2.58 |
| rs1041163 | VCAM1 | .10 | TT | 69.4 | 1.35 | 0.88-2.08 |
| rs5361 | SELE‖ | .12 | AC/CC | 17.0 | 1.41 | 0.74-2.66 |
| rs2107356 | IL4R | .14 | CC/CT | 82.4 | 1.97 | 1.01-3.83 |
| rs1799724 | TNF | .15 | CC | 83.4 | 1.35 | 0.78-2.34 |
Observed P value from the trend test (codominant model) from Table S1.
SNPs recoded as 0 for low-risk genotype(s) and 1 for deleterious genotype(s) based on results from Table S1. Missing genotype data were included with the low-risk category.
Hazard ratio (HR) adjusted for age and clinical and demographic factors. The HR is based on assigning missing SNP data to the reference group (low-risk genotype).
SNPs with a MAF less than 0.05 (not eligible for the multi-SNP risk score).
SNPs that were only genotyped in patients with a blood-based DNA sample (N = 215) were not eligible for the multi-SNP risk score.